Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2020 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Announces $2 Million Funding Commitment Allowing Option Exercise with UWM Research Foundation, Inc. and Entry into a License Agreement for GABA(A) Receptor Allosteric Neuromodulator Intellectual Property

Glen Rock, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), has historically been and remains a leader in the research and...
March 04, 2020 09:00 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Announces Entry into Option Agreement to License GABA(A) Receptor Allosteric Neuromodulator Intellectual Property from the UWM Research Foundation, Inc.

Glen Rock, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of ampakines for a variety...